Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Carroll

Showing results (1241-1250 of 1,434) with videos related to

Pageof 144
Sort By:
Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.
The Journal of Molecular Diagnostics : JMD|March 6, 2016
Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy SpecimensBeatrice S Knudsen, Hyung L Kim, Nicholas Erho, et al.
Cancer Epidemiology|September 25, 2021
Analgesic use and the risk of renal cell carcinoma - Findings from the Consortium for the Investigation of Renal Malignancies (CONFIRM) studyF J Bruinsma, S Jordan, J K Bassett, et al.
Headache|October 15, 2025
The contribution of lumbar puncture opening pressure in the diagnosis of spontaneous intracranial hypotension: A systematic literature review and meta-analysisSimy K Parikh, Constance R Deline, Morgan McCreary, et al.
The Journal of Urology|February 26, 2021
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup>F-DCFPyL in Prostate Cancer Patients (OSPREY)Kenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
European Urology Oncology|August 15, 2019
Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate CancerMelody J Xu, Zachary Kornberg, Adam J Gadzinski, et al.
Molecular Cancer Therapeutics|April 8, 2010
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancerWilliam M Merritt, Alpa M Nick, Amy R Carroll, et al.
European Urology|February 14, 2018
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance StudyJames T Kearns, Anna V Faino, Lisa F Newcomb, et al.
European Urology|March 31, 2015
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk CalculatorDonna P Ankerst, Jing Xia, Ian M Thompson, et al.
Annals of Internal Medicine|November 29, 2017
Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance CohortsLurdes Y T Inoue, Daniel W Lin, Lisa F Newcomb, et al.
Pageof 144

Showing results (1241-1250 of 1,434) with videos related to

Sort By:
Pageof 144
Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.
The Journal of Molecular Diagnostics : JMD|March 6, 2016
Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy SpecimensBeatrice S Knudsen, Hyung L Kim, Nicholas Erho, et al.
Cancer Epidemiology|September 25, 2021
Analgesic use and the risk of renal cell carcinoma - Findings from the Consortium for the Investigation of Renal Malignancies (CONFIRM) studyF J Bruinsma, S Jordan, J K Bassett, et al.
Headache|October 15, 2025
The contribution of lumbar puncture opening pressure in the diagnosis of spontaneous intracranial hypotension: A systematic literature review and meta-analysisSimy K Parikh, Constance R Deline, Morgan McCreary, et al.
The Journal of Urology|February 26, 2021
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup>F-DCFPyL in Prostate Cancer Patients (OSPREY)Kenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
European Urology Oncology|August 15, 2019
Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate CancerMelody J Xu, Zachary Kornberg, Adam J Gadzinski, et al.
Molecular Cancer Therapeutics|April 8, 2010
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancerWilliam M Merritt, Alpa M Nick, Amy R Carroll, et al.
European Urology|February 14, 2018
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance StudyJames T Kearns, Anna V Faino, Lisa F Newcomb, et al.
European Urology|March 31, 2015
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk CalculatorDonna P Ankerst, Jing Xia, Ian M Thompson, et al.
Annals of Internal Medicine|November 29, 2017
Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance CohortsLurdes Y T Inoue, Daniel W Lin, Lisa F Newcomb, et al.
Pageof 144